Toxicity profile as assessed by NCI CTC version 3.0 [clinicaltrials_resource:1094ec1349b4e673fe5c9ff7af518c78]
Patients are assigned to 1 of 2 sequential treatment groups. GROUP 1 (RESECTION CAVITY ADMINISTRATION): Patients undergo en block resection of their tumor (after confirming diagnosis) on day 1, followed by recombinant measles virus encoding human carcinoembryonic antigen (MV-CEA) administered into the resection cavity over 10 minutes.
GROUP 2 (INTRATUMORAL AND RESECTION CAVITY ADMINISTRATION): Patients undergo stereotactic biopsy (to confirm the diagnosis) and placement of a catheter within the tumor, followed by MV-CEA administration into the tumor through the catheter over 10 minutes on day 1. Patients undergo en block resection of their tumor with computer-assisted stereotactic techniques on day 5, followed by MV-CEA administered around the tumor bed.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Toxicity profile as assessed by NCI CTC version 3.0 [clinicaltrials_resource:1094ec1349b4e673fe5c9ff7af518c78]
Patients are assigned to 1 of 2 sequential treatment groups. GROUP 1 (RESECTION CAVITY ADMINISTRATION): Patients undergo en block resection of their tumor (after confirming diagnosis) on day 1, followed by recombinant measles virus encoding human carcinoembryonic antigen (MV-CEA) administered into the resection cavity over 10 minutes.
GROUP 2 (INTRATUMORAL AND RESECTION CAVITY ADMINISTRATION): Patients undergo stereotactic biopsy (to confirm the diagnosis) and placement of a catheter within the tumor, followed by MV-CEA administration into the tumor through the catheter over 10 minutes on day 1. Patients undergo en block resection of their tumor with computer-assisted stereotactic techniques on day 5, followed by MV-CEA administered around the tumor bed.
Bio2RDF identifier
1094ec1349b4e673fe5c9ff7af518c78
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:1094ec1349b4e673fe5c9ff7af518c78
measure [clinicaltrials_vocabulary:measure]
Toxicity profile as assessed by NCI CTC version 3.0
description
Patients are assigned to 1 of ...... nistered around the tumor bed.
identifier
clinicaltrials_resource:1094ec1349b4e673fe5c9ff7af518c78
title
Toxicity profile as assessed by NCI CTC version 3.0
@en
type
label
Toxicity profile as assessed b ...... 4ec1349b4e673fe5c9ff7af518c78]
@en